Skip to main content

Table 2 Treatment patterns

From: Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

 

DMT-treated patients

First Treatment Course

Oral

Injectable

Infusion

Duration of follow-up (mean, SD), mo

62.3

30.1

51.7

25.1

63.6

30.5

61.5

29.6

First DMT treatment course

Patients with first DMT course (n, %)

14,627

100

1583

100

12,796

100

248

100

Time to first DMT (mean, SD), mo

5.7

12.7

16.2

22.7

4.1

9.5

18.1

24.4

Time on first DMT (mean, SD), mo

28.1

25.9

21.0

17.5

29.0

26.7

27.2

25.4

First DMT end (n, %)

 Switch

2450

16.7

140

8.8

2287

17.9

23

9.3

 Discontinuation (≥60-day gap)

7447

50.9

741

46.8

6613

51.7

93

37.5

 End of follow-up period

4730

32.3

702

44.3

3896

30.4

132

53.2

Second DMT treatment course

Patients with second DMT (n, %)

7510

51.3

541

34.2

6898

53.9

71

28.6

Treatment gap (mean, SD), mo

5.1

9.3

4.6

6.4

5.2

9.6

5.9

7.7

Time on second DMT (mean, SD), mo

15.1

17.4

11.7

11.7

15.3

17.7

13.7

15.3

Second DMT end (n, %)

 Switcha

899

12.0

42

7.8

845

12.2

12

16.9

 Discontinuation (≥60-day gap)a

4172

55.6

277

51.2

3856

55.9

39

54.9

 End of follow-up perioda

2439

32.5

222

41.0

2197

31.8

20

28.2

Third DMT treatment course

Patients with third DMT (n, %)

3882

26.5

200

12.6

3645

28.5

37

14.9

Treatment gap (mean, SD), mo

5.0

7.2

4.7

6.0

5.0

7.3

3.8

5.4

Time on third DMT (mean, SD), mo

11.7

13.9

8.8

9.3

11.9

14.1

13.8

15.2

Third DMT end (n, %)

 Switchb

428

11.0

15

7.5

404

11.1

9

24.3

 Discontinuation (≥60-day gap)b

2248

57.9

100

50.0

2131

58.5

17

45.9

 End of follow-up periodb

1206

31.1

85

42.5

1110

30.5

11

29.7

  1. aPercentage calculated from number of patients with second-course DMT
  2. bPercentage calculated from number of patients with third-course DMT